Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma names president Carolyn Bonner as new CFO
Medicus Pharma (NASDAQ:MDCX) announced that Carolyn Bonner, who currently serving as the company's president, has been appointed to the role of chief financial officer (CFO). Bonner has been acting CFO since September 12, filling the role during the medical leave of former finance chief Jim Quinlan, who has now resigned from the company for health reasons.
Medicus Pharma spotlights new approaches to prostate and skin cancer during Men's Health Awareness Month
Medicus Pharma (NASDAQ:MDCX) marked Men's Health Awareness Month on Monday by underscoring new academic research focused on improving treatment options for prostate and skin cancers, two of the most common cancers affecting men. The biotechnology and life sciences company is advancing the clinical development of novel therapeutic candidates, including non-invasive treatments for basal cell skin cancer and next-generation therapies for advanced prostate conditions.
Medicus Pharma seeks FDA priority voucher for non-invasive skin cancer therapy
Medicus Pharma (NASDAQ:MDCX) said on Monday it has applied for a US Food and Drug Administration Commissioner's National Priority Voucher (CNPV) to accelerate review of SkinJect, its investigational microneedle patch designed to non-invasively treat basal cell carcinoma (BCC). The application includes a Statement of Interest outlining how SkinJect's Doxorubicin Microneedle Array (D-MNA) aligns with the FDA's national priorities, which focus on improving cancer care access, affordability and options for patients with rare diseases, the company said.
Medicus Pharma adds UK site to Skinject study - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the latest expansion of the company's Phase 2 clinical trial for Skinject, its lead noninvasive therapy for basal cell carcinoma. The company recently received approval from the UK Regulatory Authority to include UK sites in the ongoing Skinject 003 study.
Medicus Pharma secures UK approval to expand Phase 2 trial of non-invasive skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) said on Thursday it has received full regulatory and ethical approvals in the UK to expand its ongoing Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array (D-MNA) treatment for basal cell carcinoma (BCC), a common form of skin cancer. The UK's Medicines and Healthcare products Regulatory Agency, Health Research Authority and Wales Research Ethics Committee granted the approvals, allowing Medicus to add clinical sites in the country to its ongoing study (SKNJCT-003), which is already underway across nine sites in the US.
Medicus Pharma eyes compassionate use approval of Skinject for Gorlin Syndrome - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's recent steps to expand compassionate access to Skinject, its lead non-invasive treatment for non-melanoma skin diseases. The initiative involves a partnership with the Gorlin Syndrome Alliance, aiming to address unmet needs for patients living with this rare genetic condition.
Medicus Pharma, Gorlin Syndrome Alliance partner to expand SKINJECT access
Medicus Pharma (NASDAQ:MDCX) has partnered with the Gorlin Syndrome Alliance (GSA) to expand compassionate access to its investigational microneedle therapy, SKINJECT, for patients suffering from Gorlin Syndrome, a rare genetic condition that causes recurring skin cancers. Under the collaboration, the two groups will pursue an Expanded Access Investigational New Drug (IND) program with the US Food and Drug Administration (FDA) to allow patients with multiple or inoperable basal cell carcinomas (BCCs) to receive SKINJECT under physician supervision.
Medicus Pharma CEO discusses latest skin cancer trial milestone - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's latest milestone in its ongoing Phase 2 clinical trial for a novel, noninvasive treatment for non-melanoma skin cancer. Bokhari shared that Medicus Pharma has now treated its first patient outside the United States, at the Cleveland Clinic Abu Dhabi, expanding the study into an international trial.
Medicus Pharma doses first patient in UAE Phase 2 skin cancer study
Medicus Pharma (NASDAQ:MDCX) announced that the first patient has been treated in the United Arab Emirates (UAE) as part of its SKNJCT-004 Phase 2 clinical study evaluating a non-invasive treatment for basal cell carcinoma (BCC) of the skin. The 36-participant study is being conducted across six sites in the UAE, with Cleveland Clinic Abu Dhabi (CCAD) serving as the principal investigator.
Medicus Pharma gets FDA backing to advance skin cancer patch
Medicus Pharma (NASDAQ:MDCX) said Monday it has received positive feedback from U.S. regulators that clears a path for the company to continue developing its experimental skin patch treatment for basal cell carcinoma, the most common form of skin cancer.
Medicus Pharma closes Antev acquisition, expands skin cancer trial - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's recent progress across its drug development pipeline. Bokhari shared that Medicus Pharma has closed its acquisition of Antev, a UK-based biotech focused on next-generation gonadotropin-releasing hormone antagonists.
Medicus Pharma closes Antev acquisition; sees $6B market potential
Medicus Pharma (NASDAQ:MDCX) reported that it has completed its previously announced acquisition of Antev Limited, a UK-based clinical-stage drug development company. Medicus said it has acquired 98.6% of the issued and outstanding shares of Antev for total consideration of about US$2.97 million in cash plus 1,603,164 common shares of Medicus.
